Citius Oncology (CTOR) Research & Development (2023 - 2026)

Citius Oncology (CTOR) has reported Research & Development for 4 consecutive years, with $256231.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 72.69% year-over-year to $256231.0 in Q2 2026; TTM through Jun 2026 was $3.4 million, a 61.77% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, up 30.32% from the prior year.
• Research & Development was $256231.0 for Q2 2026 at Citius Oncology, down from $1.1 million in the prior quarter.
• Over five years, Research & Development peaked at $3.6 million in Q2 2024 and troughed at $256231.0 in Q2 2026.
• A 4-year average of $1.6 million and a median of $1.1 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 25.7% in 2025, down 74.14% in 2025.
• Over 4 years, Research & Development stood at $1.1 million in 2023, then rose by 10.1% to $1.3 million in 2024, then slipped by 19.47% to $1.0 million in 2025, then tumbled by 74.84% to $256231.0 in 2026.
• The last three Research & Development figures came in at $256231.0 (Q2 2026), $1.1 million (Q1 2026), and $1.0 million (Q4 2025), per Business Quant data.